Bunge Limited
BG
$123.70
+2.08%
Bunge Global SA is a leading global agribusiness and food company, operating at the intersection of agriculture and consumer goods by connecting farmers to consumers and delivering essential food, feed, and fuel. The company is a major player in the agricultural supply chain, with a distinct competitive identity as an integrated processor and merchandiser of oilseeds and grains, particularly dominant in soybean processing and refining. The current investor narrative is shaped by the company's ambitious long-term strategic goals, including a target for $15 in mid-cycle EPS by 2030, which signals strong management confidence in structural profitability improvements, even as the stock contends with near-term volatility in commodity markets and profit headwinds from cyclical factors.…
BG
Bunge Limited
$123.70
Related headlines
BG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bunge Limited's 12-month outlook, with a consensus price target around $160.81 and implied upside of +30.0% versus the current price.
Average Target
$160.81
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$99 - $161
Analyst target range
Analyst coverage for Bunge Global appears limited, with data indicating only 3 analysts providing estimates for revenue and EPS, which suggests the stock may have less institutional research coverage than larger-cap peers, potentially leading to higher volatility and less efficient price discovery. The available data shows estimated EPS for the consensus period has a range from $10.83 to $11.65, with an average of $11.25, and estimated revenue ranges from $94.9 billion to $97.5 billion, averaging $96.2 billion; however, a consensus price target and explicit Buy/Hold/Sell distribution are not provided in the dataset, preventing a calculation of implied upside or downside. The institutional ratings data shows a consistently bullish sentiment among major firms, with recent actions from JP Morgan, Morgan Stanley, BMO Capital, and UBS all maintaining 'Overweight,' 'Outperform,' or 'Buy' ratings, indicating strong professional conviction in the stock's outlook despite near-term challenges, with the tight clustering of bullish ratings suggesting lower uncertainty and stronger conviction among those who do cover the name.
Bulls vs Bears: BG Investment Factors
The investment debate for BG centers on the tension between its compelling long-term strategic vision and severe near-term cyclical pressures. The bull case is anchored by ambitious 2030 EPS targets, a reasonable forward valuation, and strong institutional conviction, while the bear case is grounded in the stark reality of collapsing profit margins and inherent business volatility. Currently, the bear side holds stronger near-term evidence, as the dramatic compression in net margin from 4.45% to 0.40% is a concrete, current headwind. The single most important factor that will resolve the thesis is whether the company can demonstrate a clear inflection point in core processing margins, proving that the $15 EPS target is achievable through structural improvements rather than just a cyclical rebound.
Bullish
- Strong Long-Term Strategic Targets: Management has set a highly ambitious mid-cycle EPS target of $15 by 2030, signaling strong confidence in structural profitability improvements beyond current cyclical headwinds. This long-term narrative, highlighted in recent news, provides a clear growth roadmap and anchors investor expectations.
- Attractive Forward Valuation: The stock trades at a forward P/E of 11.09x, a significant discount to its trailing P/E of 17.95x, implying the market expects a substantial earnings recovery. This forward multiple appears reasonable for a stable, asset-heavy business in the Consumer Defensive sector.
- Robust Long-Term Price Momentum: BG has significantly outperformed the market, with a 1-year price change of +55.15% versus the SPY's +27.88%. The stock trades at 80% of its 52-week range ($71.60 to $133.93), confirming a sustained primary uptrend.
- Strong Institutional Conviction: Major firms like JP Morgan, Morgan Stanley, BMO Capital, and UBS maintain 'Overweight' or 'Buy' ratings, indicating strong professional conviction. This clustering of bullish ratings suggests lower uncertainty among the analysts who cover the name.
Bearish
- Severe Cyclical Profit Compression: Profitability has collapsed from recent peaks, with Q4 2025 net margin at 0.40% versus 4.45% a year ago. Gross margin fell to 4.25% from 7.98%, reflecting intense pressure from normalized agricultural processing spreads and input costs.
- Recent Momentum Divergence & Weakness: The stock has shown significant short-term underperformance, with a 1-month decline of -4.02% and a 3-month dip of -1.02%, contrasting with the SPY's positive returns. This negative relative strength of -8.86 suggests a consolidation or profit-taking phase after the strong run.
- Extreme Revenue & Cash Flow Volatility: The business model is highly cyclical and working capital-intensive, evidenced by Q4 2025 operating cash flow of $1.34 billion versus a negative -$1.07 billion in Q2 2025. This inconsistency makes financial health and valuation challenging to assess quarter-to-quarter.
- Limited Analyst Coverage: Only 3 analysts provide estimates for revenue and EPS, suggesting less institutional research coverage than peers. This can lead to higher volatility, less efficient price discovery, and a lack of a clear consensus price target for investors to benchmark against.
BG Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a robust 1-year price change of +55.15%, significantly outperforming the SPY's +27.88% gain. Currently trading at $120.71, the price sits at approximately 80% of its 52-week range ($71.60 to $133.93), indicating it is closer to recent highs than lows, which reflects strong momentum but also suggests potential for near-term consolidation or pullback after such a significant run. Recent momentum has diverged from the longer-term trend, showing deceleration with a 1-month decline of -4.02% and a 3-month dip of -1.02%, contrasting sharply with the SPY's positive returns over the same periods (+4.84% and +8.15%, respectively). This short-term weakness, highlighted by a negative relative strength of -8.86 over one month, could signal a healthy consolidation or profit-taking phase within the broader uptrend, rather than a reversal. Key technical levels are clearly defined, with immediate support at the 52-week low of $71.60 and major resistance at the 52-week high of $133.93; a decisive breakout above $133.93 would confirm the resumption of the primary bull trend, while a breakdown below key moving averages would test investor conviction. The stock's beta of 0.627 indicates it is approximately 37% less volatile than the broader market, which is atypical for a commodity-linked business but suggests it may offer a defensive characteristic during market downturns, a factor important for risk-adjusted portfolio construction.
Beta
0.63
0.63x market volatility
Max Drawdown
-15.4%
Largest decline past year
52-Week Range
$72-$134
Price range past year
Annual Return
+55.8%
Cumulative gain past year
| Period | BG Return | S&P 500 |
|---|---|---|
| 1m | -2.1% | +6.0% |
| 3m | +2.5% | +10.0% |
| 6m | +28.8% | +10.4% |
| 1y | +55.8% | +28.4% |
| ytd | +33.5% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BG Fundamental Analysis
Revenue growth has been volatile but showed a significant year-over-year surge in the most recent quarter, with Q4 2025 revenue of $23.76 billion representing a substantial 75.47% increase from the prior-year period; however, this masks a multi-quarter trend of deceleration from peak profitability periods in 2024, as sequential revenue from Q3 2025's $22.16 billion increased only modestly, indicating the top-line is subject to large commodity price swings rather than consistent organic expansion. Profitability has compressed notably from cyclical highs, with Q4 2025 net income at $95 million and a net margin of just 0.40%, a stark contrast to the Q4 2024 net income of $602 million and net margin of 4.45%; gross margin for the latest quarter was 4.25%, down from 7.98% a year ago, reflecting pressure from normalized agricultural commodity processing spreads and potentially higher input costs. The balance sheet and cash flow position remains manageable, with a debt-to-equity ratio of 0.98 indicating a balanced capital structure, a current ratio of 1.61 showing sufficient short-term liquidity, and trailing twelve-month free cash flow of $296 million; however, quarterly operating cash flow has been inconsistent, with Q4 2025 at $1.34 billion but Q2 2025 negative at -$1.07 billion, highlighting the working capital-intensive and cyclical nature of the business where financial health is more about navigating cycles than generating steady, predictable cash flows.
Quarterly Revenue
$23.8B
2025-12
Revenue YoY Growth
+0.75%
YoY Comparison
Gross Margin
+0.04%
Latest Quarter
Free Cash Flow
$296000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BG Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 17.95x, while the forward PE is notably lower at 11.09x; this significant gap implies the market expects a substantial recovery in earnings over the next twelve months, aligning with management's mid-cycle EPS targets. Compared to sector averages, Bunge's trailing PE of 17.95x is difficult to contextualize precisely without a provided industry average, but its forward multiple of 11.09x appears reasonable for a stable, asset-heavy business in the Consumer Defensive sector, suggesting the stock is not egregiously overvalued relative to its earnings prospects. Historically, the current trailing PE of 17.95x sits well below its own recent peaks seen in 2024 (e.g., 4.46x at year-end 2024, though that was on exceptionally high earnings) and is more aligned with its multi-year average, indicating the valuation has normalized from extreme cyclical highs and currently prices in a more moderate, sustainable level of profitability rather than peak-cycle optimism.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~54x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BG faces significant financial risks stemming from the cyclical and volatile nature of its agribusiness model. Profitability is highly sensitive to commodity processing spreads, as evidenced by the severe compression in Q4 2025 net margin to 0.40% from 4.45% a year ago. The balance sheet, while manageable with a debt-to-equity of 0.98, must navigate large swings in working capital, leading to inconsistent operating cash flow that ranged from -$1.07 billion to +$1.34 billion in recent quarters. This earnings volatility makes it difficult to sustain dividends or predictable capital returns, challenging the valuation case which depends on forward earnings recovery.
Market & Competitive Risks: The primary market risk is valuation compression if the anticipated earnings rebound fails to materialize. The stock trades at a forward P/E of 11.09x, which prices in a significant recovery; disappointment could lead to multiple contraction. As a commodity processor, BG is exposed to global agricultural supply/demand shocks, trade policy changes, and competitive pressure from other integrated giants. Its low beta of 0.627 offers some market defense but does not insulate it from sector-specific downturns. The recent negative price momentum relative to the market (-8.86 over one month) may also trigger technical selling and reflect growing investor impatience with the profit cycle.
Worst-Case Scenario: The worst-case scenario involves a prolonged downturn in global agricultural commodity margins, exacerbated by a recession reducing demand for food, feed, and fuel. This could prevent the earnings recovery implied by the forward P/E, leading to consecutive quarterly misses and a downgrade of the long-term $15 EPS target. In this adverse scenario, the stock could re-test its 52-week low of $71.60, representing a downside of approximately -41% from the current price of $120.71. A more realistic severe bear case might see a drawdown to the $90-$100 range, aligning with previous support levels and representing a -17% to -25% loss.